Daniel Karp

Daniel leads our global corporate development team, including mergers & acquisitions, licensing, collaborations, alliance management, integration and corporate strategy. Under his leadership, the team evaluates and executes a broad range of strategic business development transactions, manages alliances with partners, and leads strategic planning, portfolio management and capital allocation. This helps drive company growth, expands the portfolio and pipeline, and accelerates Organon’s achievement of its long-term vision.

Prior to joining Organon, Daniel served as Executive Vice President, Corporate Development at Biogen. Previously, he held a number of positions of increasing responsibility at Pfizer, including VP, Head of BD for Worldwide Research & Development, and VP, Head of BD for Pfizer Vaccines, Oncology and Consumer Healthcare. Throughout his career, Daniel and his teams have executed M&A and collaboration deals totaling over $80B in potential value. Most importantly, these transactions have brought new drugs, gene therapies, vaccines, devices, and technologies closer to the patients who need them. Earlier in his career, Daniel held roles in healthcare and life sciences strategy consulting.

Daniel has a B.S. in biology from Duke University and an M.B.A. from the Wharton School of the University of Pennsylvania. Currently, he serves as Director on the board of Cartesian Growth Corp II and previously served on the board of Cartesian Growth Corp, which combined with Tiedemann Group and Alvarium Investments.